BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 03/17/2014
Entire Document
 
zk1414598.htm


 
SECURITIES AND EXCHANGE COMMISSION
 
WASHINGTON, D.C. 20549
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of March 2014
 
_______________________
 
BioLineRx Ltd.
 
 (Translation of registrant’s name into English)
 
_______________________
 
P.O. Box 45158
19 Hartum Street
Jerusalem 91450, Israel
 
 (Address of Principal Executive Offices)
 
_______________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:         
 
Form 20-F x   Form 40-F o
 
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
           
Yes o   No x
 
 
 

 
 
On March 17, 2014, the registrant will issue the press release which is filed as Exhibit 1 to this Report on Form 6-K.
 
This Form 6-K, including all exhibits hereto, is hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
 
 
 

 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
BioLineRx Ltd.
 
       
 
By:
/s/ Philip Serlin  
   
Philip Serlin
 
   
Chief Financial and Operating Officer
 
 Dated: March 17, 2014